Twist Bioscience Stock (NASDAQ:TWST)
Previous Close
$32.78
52W Range
$23.30 - $55.33
50D Avg
$30.85
200D Avg
$32.98
Market Cap
$1.92B
Avg Vol (3M)
$1.74M
Beta
2.24
Div Yield
-
TWST Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
TWST Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Sep 25 | Sep 24 | Sep 23 |
|---|---|---|---|
| Dna And Biopharma Libraries | $11.18M | $13.93M | $10.20M |
| Ngs Tools | $208.10M | $169.13M | $123.71M |
| Oligo Pools | $20.23M | $16.91M | $14.49M |
| Synthetic Genes | $113.60M | $92.68M | $73.54M |
| Antibody Discovery | $23.45M | $20.33M | $23.17M |
Fiscal year ends in Sep 25 | Currency in USD